NCT05544058

Brief Summary

The present study aims to collect data regarding the history of the disease, previous and current treatments, and the clinical status of Dravet patients during the 3 months prior to stiripentol initiation, the first 3 months on stiripentol and the last 3 months on stiripentol (irrespective of stiripentol discontinuation).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 27, 2022

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

August 24, 2022

Completed
23 days until next milestone

First Posted

Study publicly available on registry

September 16, 2022

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 28, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 28, 2024

Completed
Last Updated

August 2, 2024

Status Verified

August 1, 2024

Enrollment Period

2.2 years

First QC Date

August 24, 2022

Last Update Submit

August 1, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • management of the Dravet syndrome

    Patient Information History of the Disease Clinical status of the patient during the 3 months preceding stiripentol treatment initiation Clinical status of the patient at stiripentol initiation Clinical status of the patient during the first 3 months of stiripentol treatment Clinical status of the patient during the last 3 months of stiripentol treatment Evolution on stiripentol

    through study completion, an average of 1 year

Secondary Outcomes (1)

  • Better detection of the Dravet syndrome

    through study completion, an average of 1 year

Interventions

Retrospective study

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patient with dravet syndrome and reated with stiripentol for a minimum of 3 months in routine practice

You may qualify if:

  • Patients diagnosed with Dravet syndrome
  • Treated with stiripentol for a minimum of 3 months in routine practice

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo clinic

Rochester, Minnesota, 55905, United States

Location

MeSH Terms

Conditions

Epilepsies, Myoclonic

Interventions

Retrospective Studies

Condition Hierarchy (Ancestors)

Epilepsy, GeneralizedEpilepsyBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesEpileptic Syndromes

Intervention Hierarchy (Ancestors)

Case-Control StudiesEpidemiologic StudiesEpidemiologic Study CharacteristicsEpidemiologic MethodsInvestigative TechniquesCohort StudiesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 24, 2022

First Posted

September 16, 2022

Study Start

April 27, 2022

Primary Completion

June 28, 2024

Study Completion

June 28, 2024

Last Updated

August 2, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will not share

Locations